Evidence map›Paper›PMID 41680237›Full record

ArticleScientific reports2026

Enhancing bioinformatics engineering by utilizing graph therapeutic properties for clinically approved antitoxin drugs in zoonotic diseases.

Muhammad Imran, Muhammad Aqib, Mehar Ali Malik, Sadia Jutt

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Muhammad ImranDepartment of Electrical Engineering, Prince Mohammad Bin Fahd University (PMU), P.O. Box 1664, Al Khobar, 31952, Saudi Arabia.
Muhammad AqibDepartment of Basic Sciences and Humanities, College of Electrical and Mechanical Engineering, National University of Sciences and Technology, Rawalpindi, Pakistan.
Mehar Ali MalikDepartment of Basic Sciences and Humanities, College of Electrical and Mechanical Engineering, National University of Sciences and Technology, Rawalpindi, Pakistan. meher.malik@ceme.nust.edu.pk.
Sadia JuttDepartment of Basic Sciences and Humanities, College of Electrical and Mechanical Engineering, National University of Sciences and Technology, Rawalpindi, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anthrax, a zoonotic disease caused by the bacterium Bacillus anthracis. It primarily affects animals and spreads to humans through direct contact or inhalation. This article examines the correlations between physicochemical properties and topological indices of the chemical structures of drugs used to mitigate anthrax disease. This study considers the clinically approved drugs, including ciprofloxacin, levaquin, doryx, penicillin tetrapropyl, and pfizerpen, etc. For the chemical structures of these drugs, we have calculated M-polynomials of various reverse topological indices, including the reverse Zagreb-type indices, reverse atom-bond connectivity index, reverse harmonic index, and reverse sum connectivity index, etc. The relationships identified through regression analysis establish quantitative structure-property relationships (QSPR), offering insights into how the molecular structure governs the physical behavior of these antitoxins, which is foundational for future drug optimization efforts. Our findings highlight the regression coefficients that achieved the lowest SE and the maximum [Formula: see text] values, indicating the strongest structure-property correlations (such as for Molecular Weight). These robust coefficients can be used to model the structural properties of chemically similar compounds.

Indexed as

AnthraxAnti-Bacterial AgentsAntitoxinsComputational BiologyZoonosesAnimalsBacillus anthracisHumansQuantitative Structure-Activity RelationshipAnti-Bacterial AgentsAntitoxinsDrug structuresM-polynomialQSPR studiesTopological indicesZoonotic disease

Identifiers

PMID41680237
PMCPMC12976125

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.